News

Article

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors

Author(s):

Fact checked by:

The MEK inhibitor PAS-004 is safe, tolerable, and generated early efficacy signals in patients with MAPK pathway–driven advanced cancers.

stock.adobe.com

stock.adobe.com

The next-generation macrocyclic MEK inhibitor PAS-004 is safe, tolerable, and generated early efficacy signals in patients with MAPK pathway–driven advanced cancers, according to preliminary findings from 2 cohorts of patients enrolled in a phase 1 trial (NCT06299839).1

In the first 2 dosing cohorts (n = 6), in which patients received PAS-004 at 2 mg or 4 mg, the agent was well tolerated with a favorable safety profile. No patients required drug-related dose interruptions, reductions, or discontinuations. No drug-related serious adverse effects (AEs) were observed at any dose, and no protocol-defined stopping criteria were met. At the 2-mg and 4-mg dose levels, investigators have reported no rash or skin toxicity, gastrointestinal toxicity, or ocular toxicity to date.

Based on these favorable safety outcomes at the 2-mg and 4-mg dose levels, Pasithea Therapeutics, the manufacturer of PAS-004, has initiated cohort 3 of the trial, which will administer the agent at 8 mg. The company has also filed a protocol amendment to increase the dosing schedule of PAS-004.

“We believe these data demonstrate a pharmacokinetic and safety profile that differentiates PAS-004 as a next-generation MEK inhibitor,” Dr Tiago Reis Marques, chief executive officer of Pasithea Therapeutics, stated in a news release. “The long half-life at approximately 70 hours and the ability to achieve a flat pharmacokinetic curve at steady-state, aim to provide a constant target inhibition while avoiding peak plasma toxicities, which is a unique pharmacokinetic profile among MEK inhibitors used for the treatment of NF1[-mutated cancers].”

The multicenter, open-label, dose-escalation, 3+3 trial is investigating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with MAPK pathway–driven advanced solid tumors harboring a documented NF1, RAF, or RAS mutation or those who have progressed on BRAF/MEK inhibitors. Eligible patients include those at least 18 years of age with histologically or cytologically diagnosed disease who have progressed on or are ineligible for standard-of-care therapy.2 Patients must have an ECOG performance status of 0 or 1, an estimated life expectancy of at least 12 weeks, and adequate organ function.

The study plans to evaluate PAS-004 in a sequential dose-escalation design at doses of 2 mg, 4 mg, 8 mg, 15 mg, 22 mg, 30 mg, 37 mg, and 45 mg. The primary end points include dose-limiting toxicities, AEs, hematology laboratory parameters, and clinical chemistry laboratory parameters. Secondary end points include apparent terminal elimination half-life in plasma, Cmax, Ctau/Ctrough, Tmax, area under the concentration versus time curve, apparent total plasma clearance, overall response rate, progression-free survival, and overall survival.

Pharmacokinetic findings showed that plasma exposure increased with increased doses of PAS-004.1 The mean half-life of the agent was 67.9 hours, and patients experienced prolonged systemic exposure with minimal fluctuation in PAS-004 plasma concentration at steady-state, with a Cmax/Cmin ratio of 1.2. At steady-state, PAS-004 levels peaked at approximately 5 hours with a Cmax of 16.2 ng/mL for the 2-mg dose and 61.3 ng/mL for the 4-mg dose.

“PAS-004 has demonstrated distinct properties that we believe are significant advantages for an oral MEK inhibitor. PAS-004 has a significantly longer half-life compared to early-generation MEK inhibitors, particularly those used for the treatment of NF1[-mutated cancers], which have half-lives of less than 8 hours,” Marques added.

“In addition, we are encouraged to see early potential signs of efficacy, with a heavily pretreated patient with colorectal cancer [CRC] showing prolonged stable disease. CRC is known to not provide a RECIST response when treated with single-agent MEK inhibitors. This patient has a BRAF K601E mutation, a mutational status with no approved therapies. We are encouraged that this patient has been treated continuously into the 6th 28-day dosing cycle with no toxicities or AEs observed. While still early in clinical development, we believe PAS-004 is showing early signs of differentiation, indicating PAS-004 has the potential to outperform current MEK inhibitors in terms of safety, reduced administration frequency, and potentially efficacy. Our goal is to provide a once-daily or less frequent dosing treatment with broader application, not only for NF1[-mutated cancers] but also for other indications,” Marques concluded.

References

  1. Pasithea Therapeutics announces positive initial safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its phase 1 clinical trial of PAS-004 in advanced cancer. News release. Pasithea Therapeutics Corp. September 26, 2024. Accessed September 27, 2024. https://ir.pasithea.com/news-events/press-releases/detail/108/pasithea-therapeutics-announces-positive-initial-safety
  2. PAS-004 in patients with advanced solid tumors. ClinicalTrials.gov. Updated September 4, 2024. Accessed September 27, 2024. https://clinicaltrials.gov/study/NCT06299839
Related Videos
Kimmie Ng, MD, MPH
Marc Machaalani, MD
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Kimmie Ng, MD, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Richard Kim, MD
Arvind N. Dasari, MD, MS
John H. Strickler, MD
Marco Davila, MD, PhD